Inari Medical to Present at Upcoming Investor Conferences
Inari Medical, Inc. (NASDAQ: NARI) announced its participation in two upcoming investor conferences. The first is the Wells Fargo Healthcare Conference on September 9, 2022, at 8:35 a.m. Eastern Time in Boston, MA, featuring a fireside chat. The second is the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022, at 8:10 a.m. Eastern Time in New York, NY, also a fireside chat. Interested parties can access live audio webcasts through the company’s website.
- None.
- None.
IRVINE, Calif., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that its management team will present at the following investor conferences:
- 2022 Wells Fargo Healthcare Conference
Fireside chat on Friday, September 9, 2022, at 8:35 a.m. Eastern Time in Boston, MA.
- Morgan Stanley 20th Annual Global Healthcare Conference
Fireside chat on Monday, September 12, 2022, at 8:10 a.m. Eastern Time in New York, NY.
A live audio webcast and replay of the Wells Fargo and Morgan Stanley conference may be accessed on the “Investor Relations” section of the company’s website at: https://www.inarimedical.com/
About Inari Medical, Inc.
Inari Medical, Inc. is a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases. Our current product offering consists of two minimally invasive, novel catheter-based mechanical thrombectomy devices that are designed to remove large clots from large vessels and eliminate the need for thrombolytic drugs. The company purpose-built its products for the specific characteristics of the venous system and the treatment of the two distinct manifestations of venous thromboembolism, or VTE: deep vein thrombosis and pulmonary embolism. The ClotTriever system is 510(k)-cleared by FDA and CE marked for the non-surgical removal of clot from peripheral blood vessels, including for the use in the treatment of deep vein thrombosis. The FlowTriever system is 510(k)-cleared by FDA and CE marked for the non-surgical removal of clot from peripheral blood vessels, including for the use in the treatment of pulmonary embolism and clot in transit in the right atrium.
Investor Contact:
ICR Westwicke
Caroline Corner
Phone +1-415-202-5678
caroline.corner@westwicke.com
FAQ
What events is Inari Medical (NARI) participating in September 2022?
Where can I access the conference presentations for Inari Medical (NARI)?
What time will Inari Medical's presentations occur during the investor conferences?
What is the focus of Inari Medical as a company?
